Enzyme therapeutics for systemic detoxi fi cation ☆ F

13 Available online xxxx 14 15 16 17 18 19

[1]  Y. Ashihara,et al.  Modification of yeast uricase with polyethylene glycol: disappearance of binding ability towards anti-uricase serum. , 1979, Enzyme.

[2]  J. Li,et al.  Construction of Robust Enzyme Nanocapsules for Effective Organophosphate Decontamination, Detoxification, and Protection , 2013, Advanced materials.

[3]  M. Jokanović.  Current understanding of the mechanisms involved in metabolic detoxification of warfare nerve agents. , 2009, Toxicology letters.

[4]  R. Wise,et al.  Anaphylactoid reactions to Dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004. , 2006, Journal of Vascular Surgery.

[5]  F. Segal,et al.  A CHARACTERIZATION OF FIBRANT SEGAL CATEGORIES , 2006, math/0603400.

[6]  A. Aiuti.  Advances in gene therapy for ADA-deficient SCID. , 2002, Current opinion in molecular therapeutics.

[7]  J. G. Kidd.  REGRESSION OF TRANSPLANTED LYMPHOMAS INDUCED IN VIVO BY MEANS OF NORMAL GUINEA PIG SERUM , 1953, The Journal of experimental medicine.

[8]  Zhen Gu,et al.  A novel intracellular protein delivery platform based on single-protein nanocapsules. , 2010, Nature nanotechnology.

[9]  J. M. Lanao,et al.  Drug, enzyme and peptide delivery using erythrocytes as carriers. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[10]  B. U. Specht,et al.  Preparation and properties of trypsin and chymotrysin coupled covalently to poly (N-vinylpyrrolidone). , 1977, Biochimica et biophysica acta.

[11]  Cheol Moon,et al.  L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[12]  J. Bomalaski,et al.  Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. , 2002, Cancer research.

[13]  C. Toumazou,et al.  Glucose sensors: a review of current and emerging technology , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[14]  I. Liener,et al.  Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase. , 2015, The American review of respiratory disease.

[15]  R. Stern,et al.  Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. , 1976, The New England journal of medicine.

[16]  H. Simmonds,et al.  A ROLE FOR PURINE METABOLISM IN THE IMMUNE RESPONSE: ADENOSINE-DEAMINASE ACTIVITY AND DEOXYADENOSINE CATABOLISM , 1978, The Lancet.

[17]  F. Veronese,et al.  Surface modification of proteins by covalent binding of acrylic polymers , 1985 .

[18]  R. Stevens,et al.  Structural studies on phenylalanine hydroxylase and implications toward understanding and treating phenylketonuria. , 2003, Pediatrics.

[19]  F. Walther,et al.  Antioxidant-surfactant liposomes mitigate hyperoxic lung injury in premature rabbits. , 1995, The American journal of physiology.

[20]  D. Ollis,et al.  Pharmacokinetics of OpdA, an organophosphorus hydrolase, in the African green monkey. , 2010, Biochemical pharmacology.

[21]  G. Bendersky.  Etiology of hyperuricemia. , 1975, Annals of clinical and laboratory science.

[22]  J. Kaye,et al.  Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Marrs,et al.  EVALUATION OF ANTIDOTES FOR POISONING BY ORGANOPHOSPHORUS PESTICIDES , 2000 .

[24]  S. Pizzo,et al.  A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function. , 1985, The Journal of clinical investigation.

[25]  J. Rodríguez-Nogales.  Kinetic behaviour and stability of glucose oxidase entrapped in liposomes , 2004 .

[26]  Charles W. Taylor,et al.  A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors , 2001, Cancer Chemotherapy and Pharmacology.

[27]  Sustained Enzyme Activity of Organophosphorus Hydrolase in Polymer Encased Multilayer Assemblies , 2003 .

[28]  I. Klebovich,et al.  Characterization of liposomal vesicles encapsulating rhodanese for cyanide antagonism , 2009, Drug delivery.

[29]  J. Bomalaski,et al.  Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. , 2002, The Journal of rheumatology.

[30]  V. Yang,et al.  Controlled release of clot-dissolving tissue-type plasminogen activator from a poly(L-glutamic acid) semi-interpenetrating polymer network hydrogel. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[31]  Wayne R. Gombotz,et al.  Biodegradable Polymers for Protein and Peptide Drug Delivery , 1995 .

[32]  G. Henze,et al.  Drug monitoring of low‐dose PEG‐asparaginase (Oncaspartm) in children with relapsed acute lymphoblastic leukaemia , 2001, British journal of haematology.

[33]  D. Harrison,et al.  Targeted Detoxification of Selected Reactive Oxygen Species in the Vascular Endothelium , 2009, Journal of Pharmacology and Experimental Therapeutics.

[34]  Robert D. Brewer,et al.  Contribution of Excessive Alcohol Consumption to Deaths and Years of Potential Life Lost in the United States , 2014, Preventing chronic disease.

[35]  I. Petrikovics,et al.  Nanoencapsulated and microencapsulated enzymes in drug antidotal therapy , 2012, Toxicology and industrial health.

[36]  C Simone Fishburn,et al.  The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. , 2008, Journal of pharmaceutical sciences.

[37]  A. Zimmer,et al.  Physicochemical characterization of stealth liposomes encapsulating an organophosphate hydrolyzing enzyme , 2009, Journal of liposome research.

[38]  M. Yoshimoto,et al.  Liposomal Encapsulation of Yeast Alcohol Dehydrogenase with Cofactor for Stabilization of the Enzyme Structure and Activity , 2008, Biotechnology progress.

[39]  Zoran Radić,et al.  Imidazole Aldoximes Effective in Assisting Butyrylcholinesterase Catalysis of Organophosphate Detoxification , 2014, Journal of medicinal chemistry.

[40]  H. Müller,et al.  Use of L-asparaginase in childhood ALL. , 1998, Critical reviews in oncology/hematology.

[41]  G. Braitberg,et al.  Treatment of cyanide poisoning in Australasia , 2000 .

[42]  M. Laguerre,et al.  In vivo accelerated acetaldehyde metabolism using acetaldehyde dehydrogenase-loaded erythrocytes. , 1990, Alcohol and alcoholism.

[43]  M. Hashida,et al.  Biochemical and biopharmaceutical properties of macromolecular conjugates of uricase with dextran and polyethylene glycol. , 1990, Chemical & pharmaceutical bulletin.

[44]  M. Keating,et al.  Clinical pharmacology of polyethylene glycol-L-asparaginase. , 1986, Drug metabolism and disposition: the biological fate of chemicals.

[45]  J. L. Way.  Cyanide intoxication and its mechanism of antagonism. , 1984, Annual review of pharmacology and toxicology.

[46]  A. Gabizon,et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Treuheit,et al.  Mono-N-terminal poly(ethylene glycol)-protein conjugates. , 2002, Advanced drug delivery reviews.

[48]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[49]  M. Wirth,et al.  Stabilisation and determination of the biological activity of L-asparaginase in poly(D,L-lactide-co-glycolide) nanospheres. , 2003, International journal of pharmaceutics.

[50]  S. Pizzo.  Preparation, in vivo properties and proposed clinical use of polyoxyethylene-modified tissue plasminogen activator and streptokinase , 1991 .

[51]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[52]  L. Frankenberg.  Enzyme therapy in cyanide poisoning: Effect of rhodanese and sulfur compounds , 1980, Archives of Toxicology.

[53]  V. Muzykantov,et al.  Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules. , 2005, Current pharmaceutical design.

[54]  Sang Bok Lee,et al.  Nanodetoxification: emerging role of nanomaterials in drug intoxication treatment. , 2011, Nanomedicine.

[55]  Roger P. Smith,et al.  Comparison of hydroxylamine, 4-dimethylaminophenol and nitrite protection against cyanide poisoning in mice , 1982, Archives of Toxicology.

[56]  D. Lewis,et al.  Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes. , 1985, Biochemical pharmacology.

[57]  Mark W Grinstaff,et al.  Biomedical applications of dendrimers: a tutorial. , 2011, Chemical Society reviews.

[58]  R. Melton,et al.  Covalent linkage of carboxypeptidase G2 to soluble dextrans--I. Properties of conjugates and effects on plasma persistence in mice. , 1987, Biochemical pharmacology.

[59]  I. Petrikovics,et al.  Nano-Intercalated Organophosphorus-Hydrolyzing Enzymes in Organophosphorus Antagonism , 2012, AAPS PharmSciTech.

[60]  N. Sakuragawa,et al.  Studies on the effect of PEG-modified urokinase on coagulation-fibrinolysis using beagles. , 1986, Thrombosis research.

[61]  R. Stern,et al.  RESTORATION OF IN-VITRO LYMPHOCYTE RESPONSES WITH EXOGENOUS ADENOSINE DEAMINASE IN A PATIENT WITH SEVERE COMBINED IMMUNODEFICIENCY , 1975, The Lancet.

[62]  A. Koide,et al.  Preparation of polyethylene glycol‐modified streptokinase with disappearance of binding ability towards anti‐serum and retention of activity , 1982, FEBS letters.

[63]  C. Clemedson,et al.  The antidote effect of some sulfur compounds and rhodanese in experimental cyanide poisoning. , 1954, Acta physiologica Scandinavica.

[64]  Ashley I. Bush,et al.  The metallobiology of Alzheimer's disease , 2003, Trends in Neurosciences.

[65]  PEG-URATE OXIDASE CONJUGATES AND USE THEREOF PEG-URICASE KONJUGATE UND VERWENDUNG DAVON CONJUGUES PEG-URATE OXYDASE ET UTILISATION ASSOCIEE , 2005 .

[66]  D. Bailey,et al.  The acetylcholinesterase oxime reactivator HI‐6 in man: Pharmacokinetics and tolerability in combination with atropine , 1995, Biopharmaceutics & drug disposition.

[67]  M. Hershfield,et al.  Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase , 2005, Arthritis research & therapy.

[68]  R H Glew,et al.  Enzyme loading of erythrocytes. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[69]  A. Wilk,et al.  Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia , 2013, Leukemia.

[70]  P. Williams.  A single dose , 2008, BDJ.

[71]  D. Maysinger,et al.  Micellar Nanocontainers Distribute to Defined Cytoplasmic Organelles , 2003, Science.

[72]  R. Perez-soler,et al.  Biological characterization of L-asparaginase liposomal formulations , 1996, Cancer Chemotherapy and Pharmacology.

[73]  R. Perez-soler,et al.  Liposomal l-asparaginase: in vitro evaluation , 1993 .

[74]  F. Raushel,et al.  Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication. , 1999, Toxicology.

[75]  R. Stevens,et al.  Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria. , 2005, Molecular genetics and metabolism.

[76]  D. Humphreys,et al.  Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering. , 2007, Protein engineering, design & selection : PEDS.

[77]  R. Taverna,et al.  Glucose transport in white erythrocyte ghosts and membrane-derived vesicles. , 1973, Biochimica et biophysica acta.

[78]  K. Kuča,et al.  Prophylaxis Against Nerve Agent Intoxications , 2006 .

[79]  Ronnie H. Fang,et al.  A biomimetic nanosponge that absorbs pore-forming toxins , 2013, Nature nanotechnology.

[80]  R. Glew,et al.  Enzymatic degradation of uric acid by uricase-loaded human erythrocytes. , 1975, The Journal of clinical investigation.

[81]  Lorenzo Leggio,et al.  Acute alcohol intoxication. , 2008, European journal of internal medicine.

[82]  F. Davis,et al.  Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase. , 1984, International archives of allergy and applied immunology.

[83]  K. Ulbrich,et al.  POLY(HPMA)-COATED LIPOSOMES DEMONSTRATE PROLONGED CIRCULATION IN MICE , 2001, Journal of liposome research.

[84]  L. P. McCarty.  Oxygen Radicals in Influenza-Induced Pathogenesis and Treatment with Pyran Polymer- Conjugated SOD??? , 1990 .

[85]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[86]  S. Prabhakar,et al.  Organophosphorus intoxication. , 2000, Archives of neurology.

[87]  M. Magnani,et al.  Comparison of uricase-bound and uricase-loaded erythrocytes as bioreactors for uric acid degradation. , 1992, Advances in experimental medicine and biology.

[88]  V. Muzykantov,et al.  Platelet-Endothelial Cell Adhesion Molecule-1-Directed Endothelial Targeting of Superoxide Dismutase Alleviates Oxidative Stress Caused by Either Extracellular or Intracellular Superoxide , 2007, Journal of Pharmacology and Experimental Therapeutics.

[89]  A M Tsatsakis,et al.  Amphiphilic poly-N-vinylpyrrolidones: synthesis, properties and liposome surface modification. , 2001, Biomaterials.

[90]  T. Chang,et al.  Phenylalanine ammonia‐lyase immobilized in semipermeable microcapsules for enzyme replacement in phenylketonuria , 1985, FEBS letters.

[91]  B. Mégarbane,et al.  Current recommendations for treatment of severe toxic alcohol poisonings , 2005, Intensive Care Medicine.

[92]  P. Rodriguez,et al.  Pegylated arginase I: a potential therapeutic approach in T-ALL. , 2010, Blood.

[93]  A H Hall,et al.  Clinical toxicology of cyanide. , 1986, Annals of emergency medicine.

[94]  Z. Suntres,et al.  Liposomal Antioxidants for Protection against Oxidant-Induced Damage , 2011, Journal of toxicology.

[95]  Geoffrey M. Cooper,et al.  The Central Role of Enzymes as Biological Catalysts , 2000 .

[96]  M. Pinilla,et al.  Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation. , 2001, Life sciences.

[97]  J R Pittman,et al.  Diagnosis and management of gout. , 1999, American family physician.

[98]  G. Gregoriadis,et al.  Penetration of target areas in the rat by liposome‐associated bleomycin, glucose oxidase and insulin , 1976, FEBS letters.

[99]  Ramanathan Nagarajan,et al.  Enhancing enzyme stability by construction of polymer-enzyme conjugate micelles for decontamination of organophosphate agents. , 2014, Biomacromolecules.

[100]  F. Davis,et al.  Reduction of plasma urate levels in the cockerel with polyethylene glycol-uricase. , 1981, The Journal of pharmacology and experimental therapeutics.

[101]  C. Abell,et al.  Phenylalanine ammonia-lyase. Induction and purification from yeast and clearance in mammals. , 1976, The Journal of biological chemistry.

[102]  D. Rutter,et al.  ENZYME ANTIDOTE FOR EXPERIMENTAL CYANIDE POISONING , 1974 .

[103]  P. Colombat,et al.  Improved pharmacodynamics of l-asparaginase-loaded in human red blood cells , 1996, European Journal of Clinical Pharmacology.

[104]  J. Cohen,et al.  Purification and properties of dialkylfluorophosphatase. , 1957, Biochimica et biophysica acta.

[105]  Y. Kawashima,et al.  Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[106]  F. Davis,et al.  Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct. , 1981, Anticancer research.

[107]  F. Davis,et al.  HYPOURICAEMIC EFFECT OF POLYETHYLENEGLYCOL MODIFIED URATE OXIDASE , 1981, The Lancet.

[108]  M. Vellard.  The enzyme as drug: application of enzymes as pharmaceuticals. , 2003, Current opinion in biotechnology.

[109]  M. Nucci,et al.  Immunogenicity of polyethylene glycol-modified superoxide dismutase and catalase. , 1986, Journal of free radicals in biology & medicine.

[110]  Mark Voorneveld,et al.  Preparation , 2018, Games Econ. Behav..

[111]  F. Veronese,et al.  Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. , 2008, Advanced drug delivery reviews.

[112]  Cornelia G Palivan,et al.  SOD antioxidant nanoreactors: influence of block copolymer composition on the nanoreactor efficiency. , 2010, Macromolecular bioscience.

[113]  Ananda B. W. Manage,et al.  Nano-intercalated rhodanese in cyanide antagonism , 2010, Nanotoxicology.

[114]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[115]  H. Sato,et al.  Enzymatic procedure for site-specific pegylation of proteins. , 2002, Advanced drug delivery reviews.

[116]  J. L. Way,et al.  Encapsulation of phosphotriesterase within murine erythrocytes. , 1994, Toxicology and applied pharmacology.

[117]  W. Stone,et al.  Therapeutic uses of antioxidant liposomes , 2004, Molecular biotechnology.

[118]  J. Liu,et al.  Preparation and characterization of lipid vesicles containing uricase , 2010, Drug delivery.

[119]  D. Shangguan,et al.  PEG-urokinase nanogels with enhanced stability and controllable bioactivity , 2012 .

[120]  P. Caliceti,et al.  Physico-Chemical and Biological Properties of Monofunctional Hydroxy Teriminating Poly(N-Vinylpyrrolidone) Conjugated Superoxide Dismutase , 1995 .

[121]  N. Tirelli,et al.  Scavenging ROS: superoxide dismutase/catalase mimetics by the use of an oxidation-sensitive nanocarrier/enzyme conjugate. , 2012, Bioconjugate chemistry.

[122]  F. Baud,et al.  Antidotes for acute cyanide poisoning. , 2012, Current pharmaceutical biotechnology.

[123]  M. Gibaldi,et al.  Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs , 2003 .

[124]  M. Hershfield,et al.  Diabetes Insipidus in Uricase-deficient Mice: a Model for Evaluating Therapy with Poly(ethylene Glycol)-modified Uricase , 2000 .

[125]  T. Chang,et al.  A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[126]  W. Hennink,et al.  A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. , 2003, Bioconjugate chemistry.

[127]  A. Ryckewaert.  [Pathogenesis of gout]. , 1966, Revue francaise d'etudes cliniques et biologiques.

[128]  A. Abuchowski,et al.  The clinical efficacy of poly(ethylene glycol)-modified proteins , 1990 .

[129]  Y. Barenholz,et al.  Local prevention of oxidative stress in the intestinal epithelium of the rat by adhesive liposomes of superoxide dismutase and tempamine. , 2005, Molecular pharmaceutics.

[130]  K. Kato,et al.  Physicochemical characterization of PEG-PPG conjugated human urokinase. , 1994, Biochimica et biophysica acta.

[131]  H. Klok,et al.  Polymer–protein conjugates: an enzymatic activity perspective , 2010 .

[132]  F. Worek,et al.  Drug development for the management of organophosphorus poisoning , 2013, Expert opinion on drug discovery.

[133]  R. Stevens,et al.  Toward PKU enzyme replacement therapy: PEGylation with activity retention for three forms of recombinant phenylalanine hydroxylase. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[134]  M. Ebadi,et al.  Oxidative stress and antioxidant therapy in Parkinson's disease , 1996, Progress in Neurobiology.

[135]  M. Wróbel,et al.  Sulfurtransferases and Cyanide Detoxification in Mouse Liver, Kidney, and Brain , 2004, Toxicology mechanisms and methods.

[136]  Y. Ashani,et al.  Enzymes as pretreatment drugs for organophosphate toxicity , 1991, Neuroscience & Biobehavioral Reviews.

[137]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[138]  Rupa Iyer,et al.  Protein engineering of representative hydrolytic enzymes for remediation of organophosphates , 2015 .

[139]  J. McCord,et al.  Oxygen-derived free radicals in postischemic tissue injury. , 1985, The New England journal of medicine.

[140]  Polymer Conjugation to Cu,Zn-SOD and Suppression of Hydroxyl Radical Generation on Exposure to H2O2: Improved Stability of SOD in Vitro and in Vivo , 1996 .

[141]  J. Dijkstra,et al.  Uptake and Intracellular Processing of Targeted and Nontargeted Liposomes by Rat Kupffer Cells In Vivo and In Vitro a , 1985, Annals of the New York Academy of Sciences.

[142]  J. Crapo,et al.  Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase. , 1984, The Journal of clinical investigation.

[143]  R. Olsen,et al.  Dihydromyricetin As a Novel Anti-Alcohol Intoxication Medication , 2012, The Journal of Neuroscience.

[144]  J. Wild,et al.  Enzyme-based intravascular defense against organophosphorus neurotoxins: Synergism of dendritic-enzyme complexes with 2-PAM and atropine , 2007 .

[145]  J. Leroux,et al.  Injectable nanocarriers for biodetoxification. , 2007, Nature nanotechnology.

[146]  M. Hershfield,et al.  PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. , 1995, Clinical immunology and immunopathology.

[147]  J. L. Way,et al.  In vitro studies on sterically stabilized liposomes (SL) as enzyme carriers in organophosphorus (OP) antagonism. , 2000, Drug delivery.

[148]  R. Mehvar.  Dextrans for targeted and sustained delivery of therapeutic and imaging agents. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[149]  C. Szabó,et al.  Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol , 2006, Pharmacological Reviews.

[150]  E. Fernandes,et al.  Progress towards the discovery of xanthine oxidase inhibitors. , 2002, Current medicinal chemistry.

[151]  P. Keegan,et al.  FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). , 2007, The oncologist.

[152]  P. Caliceti,et al.  Synthesis and molecular weight characterization of low molecular weight end‐functionalized poly(4‐acryloylmorpholine) , 1994 .

[153]  J. Jackson,et al.  Polyethylene glycol-attached antioxidant enzymes decrease pulmonary oxygen toxicity in rats. , 1989, Journal of applied physiology.

[154]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[155]  D. Porter,et al.  In vivo detoxification of cyanide by cystathionase γ-lyase , 1996 .

[156]  Tatiana Segura,et al.  Controlled Protein Delivery Based on Enzyme‐Responsive Nanocapsules , 2011, Advanced materials.

[157]  R. Macgregor,et al.  Effect of acute alcohol intoxication on granulocyte mobilization and kinetics. , 1978, Blood.

[158]  R. Duncan.  The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.

[159]  A Heller,et al.  Implanted electrochemical glucose sensors for the management of diabetes. , 1999, Annual review of biomedical engineering.

[160]  Jiang Yuan,et al.  A novel zwitterionic copolymer with a short poly(methyl acrylic acid) block for improving both conjugation and separation efficiency of a protein without losing its bioactivity. , 2013, Journal of materials chemistry. B.

[161]  T. Philip,et al.  Tolerance Evaluation of L-asparaginase loaded in red blood cells , 1996, European Journal of Clinical Pharmacology.

[162]  P. Caliceti,et al.  Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. , 2003, Advanced drug delivery reviews.

[163]  Y. Xiong,et al.  Amphiphilic cholic-acid-modified dextran sulfate and its application for the controlled delivery of superoxide dismutase. , 2012, Macromolecular bioscience.

[164]  E. Giblett,et al.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. , 1972, Lancet.

[165]  L. Unsworth,et al.  Poly(ethylene glycol) and Poly(carboxy betaine) Based Nonfouling Architectures: Review and Current Efforts , 2012 .

[166]  J. Creeth,et al.  Reactive liposomes encapsulating a glucose oxidase-peroxidase system with antibacterial activity. , 1997, Biochimica et biophysica acta.

[167]  R. Stevens,et al.  Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[168]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[169]  J. Hoskins,et al.  ENZYMATIC CONTROL OF PHENYLALANINE INTAKE IN PHENYLKETONURIA , 1980, The Lancet.

[170]  J. Grimsley,et al.  Improved pharmacokinetics and immunogenicity profile of organophosphorus hydrolase by chemical modification with polyethylene glycol. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[171]  P. Caliceti,et al.  Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine). , 2000, Farmaco.

[172]  F. Veronese,et al.  Stabilization of substances in circulation. , 1998, Bioconjugate chemistry.

[173]  D. Liska.  The detoxification enzyme systems. , 1998, Alternative medicine review : a journal of clinical therapeutic.

[174]  A. Kabanov,et al.  Pluronic-modified superoxide dismutase 1 attenuates angiotensin II-induced increase in intracellular superoxide in neurons. , 2010, Free radical biology & medicine.

[175]  Y. Surh,et al.  Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. , 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[176]  F. Haaf,et al.  Polymers of N-Vinylpyrrolidone: Synthesis, Characterization and Uses , 1985 .

[177]  R. Kobayashi,et al.  Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. , 1987, The New England journal of medicine.

[178]  R. Fernández-Lafuente,et al.  Structural and Functional Stabilization of L‐Asparaginase via Multisubunit Immobilization onto Highly Activated Supports , 2001, Biotechnology progress.

[179]  P. Caliceti,et al.  Branched and Linear Poly(Ethylene Glycol): Influence of the Polymer Structure on Enzymological, Pharmacokinetic, and Immunological Properties of Protein Conjugates , 1997 .

[180]  C Lizano,et al.  In vitro study of alcohol dehydrogenase and acetaldehyde dehydrogenase encapsulated into human erythrocytes by an electroporation procedure. , 1998, Biochimica et biophysica acta.

[181]  G. Boss,et al.  Cyanide Detoxification by the Cobalamin Precursor Cobinamide , 2006, Experimental biology and medicine.

[182]  Yang Liu,et al.  Biomimetic enzyme nanocomplexes and their use as antidotes and preventive measures for alcohol intoxication. , 2013, Nature nanotechnology.

[183]  P. Caliceti,et al.  Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers. , 1999, Bioconjugate chemistry.

[184]  M. Graham.  Pegaspargase: a review of clinical studies. , 2003, Advanced drug delivery reviews.

[185]  J. L. Way,et al.  Antagonism of paraoxon intoxication by recombinant phosphotriesterase encapsulated within sterically stabilized liposomes. , 1999, Toxicology and applied pharmacology.

[186]  Francesco M Veronese,et al.  Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. , 2002, Advanced drug delivery reviews.

[187]  A. Seligman,et al.  Polyvinyl pyrrolidone as a plasma expander; studies on its excretion, distribution and metabolism. , 1952, The New England journal of medicine.

[188]  S. Müller,et al.  New modified β-cyclodextrin derivatives as detoxifying agents of chemical warfare agents (II). In vitro detoxification of cyclosarin (GF): general screening and toxicokinetic aspects of OP scavengers. , 2013, Toxicology letters.

[189]  Ming Yan,et al.  Protein nanocapsule weaved with enzymatically degradable polymeric network. , 2009, Nano letters.

[190]  R. Villalonga,et al.  Glycosidation of cu,zn-superoxide dismutase with end-group aminated dextran: pharmacological and pharmacokinetics properties. , 2005, Macromolecular bioscience.

[191]  Dmitry Nevozhay,et al.  Antitumor properties and toxicity of dextran-methotrexate conjugates are dependent on the molecular weight of the carrier. , 2006, Anticancer research.

[192]  C. Deslauriers,et al.  Hydroxocobalamin as a Cyanide Antidote , 2006, American journal of therapeutics.

[193]  S. Pizzo,et al.  Catabolism of streptokinase and polyethylene glycol-streptokinase: evidence for transport of intact forms through the biliary system in the mouse. , 1990, Blood.

[194]  R. Perez-soler,et al.  Liposomal palmitoyl-L-asparaginase: characterization and biological activity , 2004, Cancer Chemotherapy and Pharmacology.

[195]  J. L. Way,et al.  Long circulating liposomes encapsulating organophosphorus acid anhydrolase in diisopropylfluorophosphate antagonism. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[196]  Jun Ge,et al.  Encapsulation of single enzyme in nanogel with enhanced biocatalytic activity and stability. , 2006, Journal of the American Chemical Society.

[197]  S. Matalon,et al.  Mitigation of oxidant injury to lung microvasculature by intratracheal instillation of antioxidant enzymes. , 1993, The American journal of physiology.

[198]  J. L. Way,et al.  In vivo studies on rhodanese encapsulation in mouse carrier erythrocytes. , 1991, Toxicology and applied pharmacology.

[199]  J. Mucklow.  Streptokinase is more economical than alteplase , 1995, BMJ.

[200]  J. Hamel.  A review of acute cyanide poisoning with a treatment update. , 2011, Critical care nurse.

[201]  G. Vawter,et al.  Adenosine deaminase deficiency: frequency and comparative pathology in autosomally recessive severe combined immunodeficiency. , 1979, Clinical immunology and immunopathology.

[202]  P. Caliceti,et al.  Immunological properties of uricase conjugated to neutral soluble polymers. , 2001, Bioconjugate chemistry.

[203]  Han‐Gon Choi,et al.  Prolonged systemic delivery of streptokinase using liposome , 1998, Archives of pharmacal research.

[204]  Gebräuchliche Fertigarzneimittel,et al.  V , 1893, Therapielexikon Neurologie.

[205]  V. Muzykantov,et al.  Loading PEG-Catalase into Filamentous and Spherical Polymer Nanocarriers , 2008, Pharmaceutical Research.

[206]  Y. Ikada,et al.  Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification , 1997 .

[207]  M. Sogorb,et al.  The role of phosphotriesterases in the detoxication of organophosphorus compounds. , 1999, Critical reviews in toxicology.

[208]  A. Finn.  Immunologic Disorders in Infants and Children. , 1997 .

[209]  M. Laguerre,et al.  Erythrocytes as Carriers for L‐Asparaginase. Methodological and Mouse In‐vivo Studies , 1990, The Journal of pharmacy and pharmacology.

[210]  H. Katinger,et al.  Topically applied liposome encapsulated superoxide dismutase reduces postburn wound size and edema formation. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[211]  G. Rockwood,et al.  Optimization of Liposomal Lipid Composition for a New, Reactive Sulfur Donor, and In Vivo Efficacy Studies on Mice to Antagonize Cyanide Intoxication , 2011, Journal of drug delivery.

[212]  F. Perez-Ruiz,et al.  PEG-uricase in the management of treatment-resistant gout and hyperuricemia. , 2008, Advanced drug delivery reviews.

[213]  F. Veronese,et al.  New Acrylic Polymers for Surface Modification of Enzymes of Therapeutic Interest and for Enzyme Immobilization , 1987, Annals of the New York Academy of Sciences.

[214]  Min Zhao,et al.  Preparation of paraoxonase‐1 liposomes and studies on their in vivo pharmacokinetics in rats , 2014, Clinical and experimental pharmacology & physiology.

[215]  J. K. Baird,et al.  Enhanced plasma persistence of therapeutic enzymes by coupling to soluble dextran. , 1977, Biochemical Journal.

[216]  Haiqiang Jin,et al.  Ultrasound-triggered thrombolysis using urokinase-loaded nanogels. , 2012, International journal of pharmaceutics.